187 related articles for article (PubMed ID: 33064977)
1. LncRNA TSLNC8 synergizes with EGFR inhibitor osimertinib to inhibit lung cancer tumorigenesis by blocking the EGFR-STAT3 pathway.
Zhou SZ; Li H; Wang ZW; Wang MH; Li N; Wang YF
Cell Cycle; 2020 Nov; 19(21):2776-2792. PubMed ID: 33064977
[TBL] [Abstract][Full Text] [Related]
2. Long Non-Coding RNAs (lncRNAs) Tumor-Suppressive Role of lncRNA on Chromosome 8p12 (TSLNC8) Inhibits Tumor Metastasis and Promotes Apoptosis by Regulating Interleukin 6 (IL-6)/Signal Transducer and Activator of Transcription 3 (STAT3)/Hypoxia-Inducible Factor 1-alpha (HIF-1α) Signaling Pathway in Non-Small Cell Lung Cancer.
Fan H; Li J; Wang J; Hu Z
Med Sci Monit; 2019 Oct; 25():7624-7633. PubMed ID: 31601776
[TBL] [Abstract][Full Text] [Related]
3. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
4. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
[TBL] [Abstract][Full Text] [Related]
5. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
Li XF; Shen WZ; Jin X; Ren P; Zhang J
Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
[TBL] [Abstract][Full Text] [Related]
6. Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.
Wu S; Luo M; To KKW; Zhang J; Su C; Zhang H; An S; Wang F; Chen D; Fu L
Mol Cancer; 2021 Jan; 20(1):17. PubMed ID: 33461557
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib.
Gu J; Qian L; Zhang G; Mahajan NP; Owonikoko TK; Ramalingam SS; Sun SY
Lung Cancer; 2020 Dec; 150():26-35. PubMed ID: 33049499
[TBL] [Abstract][Full Text] [Related]
8. Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling.
Takahashi S; Noro R; Seike M; Zeng C; Matsumoto M; Yoshikawa A; Nakamichi S; Sugano T; Hirao M; Matsuda K; Hamada M; Gemma A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33924522
[TBL] [Abstract][Full Text] [Related]
9. Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma.
Jin R; Wang X; Zang R; Liu C; Zheng S; Li H; Sun N; He J
Cancer Lett; 2020 Jul; 483():46-58. PubMed ID: 32272148
[TBL] [Abstract][Full Text] [Related]
10. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun SY
Cancer; 2020 Jan; 126(9):2024-2033. PubMed ID: 31999837
[TBL] [Abstract][Full Text] [Related]
11. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
[TBL] [Abstract][Full Text] [Related]
12. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R
J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC).
Bracht JWP; Karachaliou N; Berenguer J; Pedraz-Valdunciel C; Filipska M; Codony-Servat C; Codony-Servat J; Rosell R
Int J Biol Sci; 2019; 15(12):2607-2614. PubMed ID: 31754333
[TBL] [Abstract][Full Text] [Related]
14. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
[TBL] [Abstract][Full Text] [Related]
15. Proliferating cell nuclear antigen promotes cell proliferation and tumorigenesis by up-regulating STAT3 in non-small cell lung cancer.
Wang L; Kong W; Liu B; Zhang X
Biomed Pharmacother; 2018 Aug; 104():595-602. PubMed ID: 29803172
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis.
Zhang S; Chen Z; Shi P; Fan S; He Y; Wang Q; Li Y; Ramalingam SS; Owonikoko TK; Sun SY
Theranostics; 2021; 11(8):3964-3980. PubMed ID: 33664875
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of lncRNA TSLNC8 promotes melanoma resistance to BRAF inhibitor PLX4720 through binding with PP1α to re-activate MAPK signaling.
Han Y; Fang J; Xiao Z; Deng J; Zhang M; Gu L
J Cancer Res Clin Oncol; 2021 Mar; 147(3):767-777. PubMed ID: 33389075
[TBL] [Abstract][Full Text] [Related]
18. Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction.
Han R; Hao S; Lu C; Zhang C; Lin C; Li L; Wang Y; Hu C; He Y
Mol Oncol; 2020 Jun; 14(6):1152-1169. PubMed ID: 32239624
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer.
Lu Y; Bian D; Zhang X; Zhang H; Zhu Z
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33200796
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of LncRNA PVT1 inhibits tumorigenesis in non-small-cell lung cancer by regulating miR-497 expression.
Guo D; Wang Y; Ren K; Han X
Exp Cell Res; 2018 Jan; 362(1):172-179. PubMed ID: 29133127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
